临床与病理杂志Issue(11)：2009-2012,4.DOI:10.3978/j.issn.2095-6959.2015.11.030
HDAC7与肿瘤血管生成及其抗血管靶点治疗的研究进展
The progress of HDAC7 and tumor angiogenesis as a theraptic target
摘要
Abstract
Histone deacetylase7 (HDAC7) ,which belongs to classⅡa HDACs, is a key factor of tumor angiogenesis. Researchers have reported that HDAC7 effected the growth and proliferation of vascular endothelial cell and changed the migratory capacity of endothelial cells. Interaction between HDAC7 and MEF2 (myocyte enhancer factor, MEF2) regulated its downstream target gene matrix metallo proteinase-10 (MMP-10), which played an important role in maintaining vascular stability and regulating angiogenesis, especially involving in the initiation and progression of solid tumors. We reviewed the mechanism of HDAC7 and its interaction withMEF2 in tumor angiogenesis, and proposed HDAC7 as an anti-angiogenesis target in tumor therapy.关键词
组蛋白去乙酰化酶/肌细胞增强因子/肿瘤血管/MMP-10Key words
HDACs/MEF2/tumour angiogenosis/MMP-10引用本文复制引用
李希(综述),陶光实(审校)..HDAC7与肿瘤血管生成及其抗血管靶点治疗的研究进展[J].临床与病理杂志,2015,(11):2009-2012,4.基金项目
2014年度中华人民共和国人力资源和社会保障部出国留学人员重点资助课题。hTis work was supported by the Key Research Foundation for the Returned Overseas Chinese Scholars, Ministry of Human Resources and Social Security of the People’s Republic of China （）
